Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)
The study is a phase II with safety lead in, single arm, study using Nal-IRI in combination with pembrolizumab. Nal-IRI will be given IV every 2 weeks starting at 50mg/m2. Pembrolizumab will be given 400mg IV every 6 weeks. Treatment will continue until progression, intolerable side effects or patient/doctor decision to discontinue treatment.
Triple Negative Breast Cancer|Brain Metastases
DRUG: Pembrolizumab|DRUG: Liposomal Irinotecan
Central Nervous System Disease Control Rate (DCR), -DCR is defined as the rate of complete response (CR) + rate of partial response (PR), and rate of stable disease (SD) at 6 months and will be determined as per modified Neuro-Oncology-Brain Metastases (RANO-BM) criteria, 6 months
Safety and tolerability as measured by the number of grade 3 and 4 adverse events, -Defined by the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v5, Through 90 days after completion of treatment (estimated to be 9 months)|Central Nervous System Objective Response Rate (ORR), -ORR will include CNS complete response (CR) + partial response (PR) and will be determined as per modified RANO-BM criteria., Through completion of treatment (estimated to be 6 months)|Non-Central Nervous System Objective Response Rate (ORR), -ORR will include confirmed complete response (CR) + confirmed partial response (PR) and will be determined as per RECIST 1.1, Through completion of treatment (estimated to be 6 months)|Progression Free Survival (PFS), -PFS is defined as the time from Day 1 of treatment until the criteria for disease progression is met as defined by RECIST 1.1 and/or RANO-BM or death as a result of any cause., Through completion of follow-up (estimated to be 3 years and 6 months)|Overall Survival (OS), -OS is defined as the time from Day 1 of treatment until death as a result of any cause., Through completion of follow-up (estimated to be 3 years and 6 months)
The study is a phase II with safety lead in, single arm, study using Nal-IRI in combination with pembrolizumab. Nal-IRI will be given IV every 2 weeks starting at 50mg/m2. Pembrolizumab will be given 400mg IV every 6 weeks. Treatment will continue until progression, intolerable side effects or patient/doctor decision to discontinue treatment.